EP Patent

EP2085397A1 — Crystalline form of abacavir

Assigned to Esteve Quimica SA · Expires 2009-08-05 · 17y expired

What this patent protects

Crystalline form of abacavir of formula (I), its preparation process which comprises the following steps: a) crystallizing abacavir from a solution of said compound in a (C 1 -C 4 )-alcohol, dichloromethane, acetonitrile/water, or mixtures thereof; b) isolating the crystalline fo…

USPTO Abstract

Crystalline form of abacavir of formula (I), its preparation process which comprises the following steps: a) crystallizing abacavir from a solution of said compound in a (C 1 -C 4 )-alcohol, dichloromethane, acetonitrile/water, or mixtures thereof; b) isolating the crystalline form of abacavir that appears in the prior step; and c) removing the solvent from the crystalline form of abacavir thus obtained. It can also be obtained by dispersion of abacavir in acetonitrile. It is useful for the preparation of pharmaceutical compositions for use in the treatment and/or prophylaxis of HIV infections.

Drugs covered by this patent

Patent Metadata

Patent number
EP2085397A1
Jurisdiction
EP
Classification
—
Expires
2009-08-05
Drug substance claim
No
Drug product claim
No
Assignee
Esteve Quimica SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.